GlassScriptPhysician profile
Emily Bellavance
NPI 1669597563
$2,985.10
in general payments reported to CMS, 2019-2025
19 companies · $94.80 in 2025
The $94.80 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.70 · 2021: $24.85 · 2022: $147 · 2023: $364 · 2024: $2,341 · 2025: $94.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,644 · Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,643.91 |
| Food and Beverage | $1,156.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $2,156.01 | 2024 | Axoguard Ha+ Nerve Protector, Axoguard Nerve Connector, Avance Nerve Graft |
| Hologic INC | $146.60 | 2022 | |
| Molli Surgical (US) INC | $146.05 | 2023 | |
| Hologic Sales and Service, LLC | $72.48 | 2023-2024 | Localizer, Coolseal Generator |
| Novartis Pharmaceuticals Corporation | $58.51 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $50.76 | 2023-2025 | Keytruda, Lynparza |
| Endomagnetics LTD | $46.89 | 2024 | Magseed, Magtrace |
| Legend Biotech USA INC. | $46.76 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $44.35 | 2024 | Exparel |
| Pharmacosmos Therapeutics INC. | $26.88 | 2023 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $25.65 | 2023 | Fruzaqla |
| Daiichi Sankyo INC. | $24.85 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $24.58 | 2024 | Onivyde, Somatuline Depot |
| Eisai INC. | $24.04 | 2023 | |
| Medtronic, INC. | $21.31 | 2023 | Ligasure |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $19.98 | 2025 | Deknatel |
| Blueprint Medicines Corporation | $18.08 | 2023 | Ayvakit |
| Lilly USA, LLC | $17.62 | 2025 | Verzenio, Jaypirca |
| Foundation Medicine, INC. | $13.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Bellavance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.